Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

• Status: Completed
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Anastrozole may be effective in preventing breast cancer.

PURPOSE: This randomized clinical trial is studying how well anastrozole works in preventing breast cancer in postmenopausal women who are at increased risk for the disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Queen Mary University of London
• Treatments: Anastrozole

Criteria

DISEASE CHARACTERISTICS:

• Meets at least 1 of the relative risk factors based on age as follows:

• 45 to 70 years of age:

• First-degree relative who developed breast cancer at ≤ 50 years of age

• First-degree relative who developed bilateral breast cancer

• Two or more first- or second-degree relatives who developed breast cancer or ovarian cancer

• Participants having both relatives who are second degree and on the opposite sides of the family must have at least one that was diagnosed at ≤ 50 years of age

• Nulliparous (or first birth at ≥ 30 years of age) and a first-degree relative who developed breast cancer

• Benign biopsy with proliferative disease and a first-degree relative who developed breast cancer

• Mammographic opacity covering at least 50% of the breast in the absence of hormone replacement therapy within the past 3 months

• 60 to 70 years of age:

• First-degree relative with breast cancer at any age

• Age at menopause ≥ 55 years

• Nulliparous or age at first birth ≥ 30 years

• 40 to 44 years of age:

• Two or more first- or second-degree relatives who developed breast cancer or ovarian cancer at ≤ 50 years of age

• First-degree relative with bilateral breast cancer who developed the first breast cancer at ≤ 50 years of age

• Nulliparous (or first birth at ≥ 30 years of age) and a first-degree relative who developed breast cancer at ≤ 40 years of age

• Benign biopsy with proliferative disease and a first-degree relative who developed breast cancer at ≤ 40 years of age

• All age groups (40 to 70 ears of age) with a 10-year risk > 5% who do not fit into the above categories are allowed

• Clearly apparent family history AND/OR other risk factors indicating appropriate increased risk of breast cancer for age

• The following prior breast conditions are allowed (for all age groups):

• Lobular carcinoma in situ

• Atypical ductal or lobular hyperplasia in a benign lesion

• Ductal carcinoma in-situ (DCIS), diagnosed within the past 6 months, and treated by mastectomy

• No evidence of breast cancer on mammogram within the past year

• Hormone receptor status:

• For patients with prior DCIS, estrogen- or progesterone-receptor status must have been positive

• Must have had greater than or equal to 5% positive cells

PATIENT CHARACTERISTICS:

Age

• 40 to 70

Sex

• Female

Menopausal status

• Postmenopausal, defined as at least 1 of the following:

• Over 60 years of age

• Bilateral oophorectomy

• ≤ 60 years of age with a uterus and amenorrhea for at least 12 months

• ≤ 60 years of age without a uterus and with follicle-stimulating hormone levels > 30 IU/L

Performance status

• Not specified

Life expectancy

• At least 10 years

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• Psychologically and physically suitable to receive 5 years of anti-estrogen therapy

• No cancer within the past 5 years except non-melanoma skin cancer or carcinoma in situ of the cervix

• No evidence of osteoporosis or fragility fractures within the spine

• Participants with a T-score > minus 4 and no more than 2 fragility fractures are allowed

• No concurrent severe disease that would place the participant at unusual risk or confound the results of the study

• No other medical condition that would preclude the ability to receive the study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• No prior tamoxifen, raloxifene, or other selective estrogen receptor modulator (SERM) use for more than 6 months in duration unless an IBIS-I participant (must have been off trial therapy for at least 5 years.

• No concurrent tamoxifen, raloxifene, or other SERM

• No concurrent estrogen-based hormone replacement therapy

• No concurrent systemic estrogen replacement therapy, including vaginal estrogen preparations

Radiotherapy

• Not specified

Surgery

• See Disease Characteristics

• No prior prophylactic mastectomy

• No concurrent prophylactic mastectomy

Other

• More than 6 months since prior investigational drugs